Skip to content

Arrhythmia and atrial remodeling

TL;DR — Hypertension increases incident AF risk in a dose-related fashion, while LVH, atrial enlargement/dysfunction, fibrosis and arterial stiffness provide a plausible HHD substrate. Across 68 cohorts, hypertension was associated with AF RR 1.50 (95% CI 1.42–1.58), with substantial heterogeneity; each 20-mm Hg higher systolic pressure carried RR 1.18 (1.16–1.21) (Aune 2023, PMID 36626102). LIFE suggests remodeling and drug choice may influence AF beyond clinic BP, but these are secondary analyses rather than an HHD-specific AF-prevention program (Wachtell 2005, PMID 15734615). Ventricular ectopy is more frequent in hypertensive LVH, yet evidence that uncomplicated LVH independently causes sustained ventricular arrhythmia or sudden death remains weak and confounded by occult coronary disease (Nadarajah 2021, PMID 33674703). Rhythm management follows AF/ventricular-arrhythmia evidence; “HHD” does not create a separate anticoagulation or device indication.

1. The pressure–atrium–AF loop

Step Candidate process Measurable signal
Pressure and pulsatile load LV afterload and arterial stiffness Office/ambulatory BP, pulse pressure
Ventricular remodeling LVH, fibrosis, impaired relaxation LV mass, GLS, CMR tissue markers
Higher filling pressure Repeated atrial stretch E/e′, exercise pressure, LA volume
Atrial remodeling Dilation, fibrosis, conduction slowing, mechanical dysfunction LA strain, P-wave indices, MRI research measures
AF onset Trigger plus permissive substrate ECG, patch/implantable monitoring
AF feedback Loss of atrial contraction, tachycardia and further dilation Burden, ventricular rate, serial atrial measures

The proposed pathological triad is left-atrial hypertension, electrical conduction slowing and mechanical dysfunction; each can reinforce the others (Eichenlaub 2021, PMID 34421634). Reviews of AF in hypertension and its candidate biomarkers stress that no single circulating marker resolves this substrate (Walker 2022, PMID 35023459; Tsioufis 2019, PMID 28990508).

2. Population association

A meta-analysis of 68 cohorts reported:

Exposure Cases / participants Adjusted association with incident AF Heterogeneity
Hypertension vs none 1,080,611 / 30,539,230 RR 1.50 (95% CI 1.42–1.58) I² 98.1%
Per 20-mm Hg systolic BP 346,471 / 14,569,396 RR 1.18 (1.16–1.21) I² 65.9%
Per 10-mm Hg diastolic BP 332,867 / 14,354,980 RR 1.07 (1.03–1.11) I² 91.5%

All estimates are from Aune 2023 (PMID 36626102). The heterogeneity and observational design preclude interpreting the RR as an HHD-specific causal effect.

3. LVH and atrial size are linked but nonredundant

In MESA, 4,942 participants without recognized cardiovascular disease had CMR and ECG phenotyping. Over median 6.9 years, 214 developed AF; CMR-LVH predicted AF with HR 2.04 (95% CI 1.15–3.62), and Sokolow–Lyon voltage product remained associated after adjustment for CMR-LVH (HR 1.83, 1.06–3.14). Adjustment for CMR LA volume attenuated both associations (Chrispin 2014, PMID 24657688).

Acute stress can expose the same substrate: among 545 adults hospitalized with community-acquired pneumonia, enlarged indexed LA area (OR 5.4) and concentric LVH (OR 2.2) independently predicted early AF, although infection-specific physiology limits generalization (Cangemi 2019, PMID 31266594).

LIFE similarly found baseline LA diameter and LV mass predicted incident AF, but LA diameter was the stronger time-varying marker (Wachtell 2010, PMID 20438307).

Marker What it captures Limitation
LA diameter Simple chamber-size surrogate Geometry incomplete
LA volume index Cumulative pressure/volume burden Late and rhythm/load dependent
LA reservoir strain Early mechanical dysfunction Vendor and rhythm dependence
P-wave duration/interatrial block Electrical remodeling Imperfect anatomical specificity
LV mass/geometry Upstream ventricular substrate Does not measure atrial fibrosis
Natriuretic peptide Wall stress and risk Obesity, CKD and AF affect level

4. LIFE as upstream-prevention evidence

Among 8,851 LIFE participants with hypertension, ECG-LVH and no baseline AF, new AF occurred in 150 assigned losartan versus 221 assigned atenolol: 6.8 versus 10.1 per 1,000 person-years, RR 0.67 (95% CI 0.55–0.83), despite similar BP reduction (Wachtell 2005, PMID 15734615).

Within a 939-person serial-echo substudy, baseline LA diameter predicted AF with adjusted HR 5.16 per cm (95% CI 2.85–9.35), while each 1-cm lower in-treatment diameter was associated with HR 0.21 (0.14–0.32), adjusted for LV mass and BP (Wachtell 2010, PMID 20438307).

Pulse pressure was the strongest single BP component predicting AF among 8,810 LIFE participants at risk; 353 (4.0%) developed AF over mean 4.9 years (Larstorp 2012, PMID 22753219).

These analyses support an upstream remodeling hypothesis. They do not establish LA shrinkage as a causal surrogate or losartan as universally superior for AF prevention.

5. AF consequences in HHD

LIFE participants with new AF had approximately twofold cardiovascular-event, threefold stroke and fivefold HF-hospitalization rates compared with those without new AF (Wachtell 2005, PMID 15734615). A LIFE synthesis linked greater reductions in LA size and LVH with lower AF and stroke under losartan-based therapy (Wachtell 2009, PMID 19124445).

Separately, lower in-treatment Cornell-product LVH was associated with fewer HF hospitalizations, reinforcing but not proving a shared remodeling pathway (Okin 2007, PMID 17785486).

Consequence HHD interaction
Stroke/systemic embolism Hypertension contributes to standard thromboembolic risk assessment
HFpEF decompensation Loss of atrial contraction and rapid rate elevate filling pressure
Tachycardia-mediated LV dysfunction Can mimic “progression” to HFrEF
Renal congestion Complicates pressure and diuretic management
Anticoagulant bleeding BP control and renal function affect safety

CHA₂DS₂-VASc and HAS-BLED were developed in AF populations, not as HHD staging systems (Lip 2010, PMID 19762550; Pisters 2010, PMID 20299623).

In the observational literature synthesized for established AF, the BP–outcome relation was not uniformly monotonic. A dose-response meta-analysis of 23 studies from 17 cohorts (n=476,750) modeled systolic and diastolic BP against outcomes with restricted cubic splines: systolic BP was U-shaped for all-cause mortality, lowest at 134 mm Hg (RR 0.92, 95% CI 0.86–0.98 versus 120 mm Hg), and diastolic BP was J-shaped, lowest at 83 mm Hg (RR 0.99, 0.97–1.02). Ischaemic stroke, intracranial haemorrhage and stroke-or-systemic-embolism instead rose monotonically with systolic BP, and the haemorrhagic gradient was the steeper one: at 140 versus 120 mm Hg the RR was 1.51 for intracranial haemorrhage against 1.08 for ischaemic stroke, widening to 1.99 versus 1.14 at 150 mm Hg. The authors propose a pragmatic systolic 120–130 mm Hg with diastolic kept above roughly 75–80 mm Hg; the meta-analysis does not establish a randomized treatment target (Shahmohamadi 2026, PMID 42663497).

The divergence between the mortality and stroke curves is the clinically important part: it is observational, confounded by reverse causation from advanced disease and anticoagulant exposure, and it does not license relaxing BP control in HHD with AF — but it does mean a single "lower is better" rule cannot be transferred from hypertension trials into an anticoagulated AF population without a target trial.

6. Detection and burden

AF detection depends on monitoring duration. A normal office ECG excludes only AF during that tracing. Intermittent symptoms, cryptogenic stroke, atrial enlargement or high-risk HHD can motivate longer monitoring in research, but an HHD-specific screening interval has not been validated.

Method Yield window Bias
12-lead ECG Seconds Misses paroxysmal AF
Holter 24–48 hours Short sampling
Patch monitor Days–weeks Episodic participation
Consumer/wearable ECG Repeated user-triggered or passive samples Algorithm and access bias
Implantable monitor Months–years Invasive; detects short uncertain episodes

Interatrial block, LA enlargement and atrial mechanical failure are related but not interchangeable constructs (Bejarano-Arosemena 2023, PMID 38068382).

7. Ventricular arrhythmia and sudden death

Older clinical literature linked hypertension, LVH, ventricular ectopy and sudden death (Dunn 1993, PMID 8258663; Messerli 1993, PMID 7685177). Mechanistic reviews describe fibrosis, altered ion-channel function and gap-junction redistribution as plausible arrhythmogenic changes (Shenasa 2015, PMID 26002387; Shenasa 2017, PMID 28285801).

The key boundary is evidence strength: human hypertensive-LVH studies consistently find more complex nonsustained ventricular arrhythmia, but trials showing progression to sustained arrhythmia or sudden death independent of occult CAD are sparse. A 2021 review concluded sustained events are more likely precipitated by CAD, electrolyte disturbance or another substrate than uncomplicated hypertensive LVH alone (Nadarajah 2021, PMID 33674703).

8. Renal denervation as an arrhythmia experiment

An 80-person randomized sham-controlled pilot enrolled older adults with HHD and resistant hypertension in sinus rhythm. Over 24 months, subclinical AF ≥6 minutes occurred in 19% after renal denervation versus 39.5% after sham, HR 0.40 (95% CI 0.17–0.96), without a significant between-group BP-change difference (Heradien 2022, PMID 35781044; NCT01990911).

ERADICATE-AF randomized 302 hypertensive patients undergoing AF ablation to pulmonary-vein isolation with or without renal denervation and reported more freedom from AF/flutter/tachycardia with the combined strategy (Steinberg 2020, PMID 31961420).

A seven-trial, 711-person meta-analysis found AF recurrence 31.3% with ablation plus denervation versus 52.9% with ablation alone, but trials were small and heterogeneous (Nawar 2022, PMID 35094013). Contemporary sham-controlled renal-denervation evidence chiefly establishes modest BP lowering, not definitive rhythm or cardiovascular outcome benefit (Vukadinović 2024, PMID 39355923).

9. Risk interpretation

Finding What it supports What it does not support
Hypertension–AF dose response Pressure is a modifiable AF risk factor HHD diagnosis from AF alone
U-shaped BP–mortality curve in established AF Non-monotonic risk once AF and anticoagulation are present A randomized BP target in AF
LA/LV remodeling predicts AF Structural risk enrichment Anticoagulation without documented AF
Losartan reduced AF vs atenolol in LIFE Treatment-regimen effect in ECG-LVH cohort Universal ARB class superiority
RDN pilot reduced subclinical AF Neuromodulation hypothesis Routine RDN for AF prevention
LVH linked to ectopy Electrical vulnerability Primary-prevention ICD indication

Open questions

  • Can an atrial cardiomyopathy definition predict AF and stroke beyond standard risk factors in HHD? (Eichenlaub 2021, PMID 34421634; Vasan 2021, PMID 34081212)
  • Does treatment-induced LA-strain or LA-volume improvement mediate lower AF incidence? (Wachtell 2010, PMID 20438307)
  • Which duration of device-detected AF in HHD has net benefit from anticoagulation? (Lip 2010, PMID 19762550; Pisters 2010, PMID 20299623)
  • Is the U-shaped systolic BP–mortality association in anticoagulated AF causal or reverse-caused, and what is the randomized target? (Shahmohamadi 2026, PMID 42663497)
  • Can the apparent antiarrhythmic effect of renal denervation replicate in adequately powered sham-controlled multicenter studies? (Heradien 2022, PMID 35781044; Shinohara 2024, PMID 38877310)

References

  1. Aune D, et al. Blood pressure, hypertension and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2023;38:145-178. PMID 36626102
  2. Walker M, et al. Atrial Fibrillation and Hypertension: "Quo Vadis". Curr Hypertens Rev. 2022;18:39-53. PMID 35023459
  3. Tsioufis C, et al. Biomarkers of Atrial Fibrillation in Hypertension. Curr Med Chem. 2019;26:888-897. PMID 28990508
  4. Eichenlaub M, et al. Left Atrial Hypertension, Electrical Conduction Slowing, and Mechanical Dysfunction - The Pathophysiological Triad in Atrial Fibrillation-Associated Atrial Cardiomyopathy. Front Physiol. 2021;12:670527. PMID 34421634
  5. Shenasa M, et al. Hypertension, left ventricular hypertrophy, and sudden cardiac death. Int J Cardiol. 2017;237:60-63. PMID 28285801
  6. Nadarajah R, et al. Is hypertensive left ventricular hypertrophy a cause of sustained ventricular arrhythmias in humans? J Hum Hypertens. 2021;35:492-498. PMID 33674703
  7. Shenasa M, et al. Left ventricular hypertrophy and arrhythmogenesis. Card Electrophysiol Clin. 2015;7:207-20. PMID 26002387
  8. Dunn FG, et al. Sudden cardiac death, ventricular arrhythmias and hypertensive left ventricular hypertrophy. J Hypertens. 1993;11:1003-10. PMID 8258663
  9. Messerli FH. Hypertension, left ventricular hypertrophy, ventricular ectopy, and sudden death. Am J Hypertens. 1993;6:335-6. PMID 7685177
  10. Wachtell K, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712-9. PMID 15734615
  11. Wachtell K, et al. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Blood Press. 2010;19:169-75. PMID 20438307
  12. Larstorp AC, et al. Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. Hypertension. 2012;60:347-53. PMID 22753219
  13. Wachtell K, et al. The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy. Ther Adv Cardiovasc Dis. 2008;2:507-13. PMID 19124445
  14. Okin PM, et al. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann Intern Med. 2007;147:311-9. PMID 17785486
  15. Cangemi R, et al. Left Atrium Dilatation and Left Ventricular Hypertrophy Predispose to Atrial Fibrillation in Patients With Community-Acquired Pneumonia. Am J Cardiol. 2019;124:723-728. PMID 31266594
  16. Chrispin J, et al. Association of electrocardiographic and imaging surrogates of left ventricular hypertrophy with incident atrial fibrillation: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2014;63:2007-13. PMID 24657688
  17. Heradien M, et al. Renal denervation prevents subclinical atrial fibrillation in patients with hypertensive heart disease: Randomized, sham-controlled trial. Heart Rhythm. 2022;19:1765-1773. PMID 35781044
  18. Shinohara K. Renal denervation for hypertensive heart disease and atrial fibrillation. Hypertens Res. 2024;47:2665-2670. PMID 38877310
  19. Steinberg JS, et al. Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial. JAMA. 2020;323:248-255. PMID 31961420
  20. Nawar K, et al. Renal denervation for atrial fibrillation: a comprehensive updated systematic review and meta-analysis. J Hum Hypertens. 2022;36:887-897. PMID 35094013
  21. Vukadinović D, et al. Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis. Circulation. 2024;150:1599-1611. PMID 39355923
  22. Lip GY, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-72. PMID 19762550
  23. Pisters R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-100. PMID 20299623
  24. Vasan RS, et al. Prognostic Significance of Echocardiographic Measures of Cardiac Remodeling in the Community. Curr Cardiol Rep. 2021;23:86. PMID 34081212
  25. Bejarano-Arosemena R, et al. Interatrial Block, Bayés Syndrome, Left Atrial Enlargement, and Atrial Failure. J Clin Med. 2023;12. PMID 38068382
  26. Shahmohamadi E, et al. Non-linear associations between blood pressure and clinical outcomes in atrial fibrillation: A systematic review and dose-response meta-analysis. Europace. 2026;:euag223. PMID 42663497